Figure 1.

Cannabidiol (CBD) ameliorates the clinical signs and disease progression of EAE induced by myelin oligodendrocyte glycoprotein (MOG). EAE was induced in C57BL/6 mice by flank s.c. immunization with MOG35-55. Clinical disease scores were recorded daily until day 30 after induction. CBD (CBD + EAE) or its vehicle (EAE group), was injected i.p. during the onset of the disease for 3 consecutive days (days 19–21; indicated by arrows). The mean clinical scores ± SD are shown. Each group consisted of 15 mice. Repeated measure anova showed significant differences between the EAE and CBD + EAE groups (P < 0.001).